Edoxaban for the Prevention of Thromboembolism in Patients with Atrial Fibrillation and Bioprosthetic Valves

Circulation

Volumn 135, Issue 13, 2017, Pages 1273-1275

  Carnicelli, Anthony P ^a   De Caterina, Raffaele ^b   Halperin, Jonathan L ^c   Renda, Giulia ^b   Ruff, Christian T ^a   Trevisan, Marco ^a   Nordio, Francesco ^a   Mercuri, Michele F ^d   Antman, Elliott ^a   Giugliano, Robert P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CHIETI   (Italy)

^c MOUNT SINAI HOSPITAL   (United States)

^d DAIICHI SANKYO INC   (United States)

Author keywords

anticoagulation; atrial fibrillation; bioprosthetic valve; edoxaban; warfarin

Indexed keywords

EDOXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANTICOAGULANT THERAPY; AORTA VALVE REPLACEMENT; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; HEART INFARCTION; HEART VALVE PROSTHESIS; HUMAN; LETTER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOEMBOLISM; THROMBOSIS PREVENTION; ADVERSE DEVICE EFFECT; BIOPROSTHESIS; BLEEDING; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DEVICES; DRUG EFFECT; HEART VALVE REPLACEMENT; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOPROSTHESIS; BLOOD COAGULATION; FACTOR XA INHIBITORS; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HUMANS; PYRIDINES; RISK FACTORS; STROKE; THIAZOLES; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN;

EID: 85013481657     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.026714     Document Type: Letter

References (5)

1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: A population-based study. Lancet. 2006;368:1005-1011. doi: 10.1016/S0140-6736(06)69208-8.
2. Isaacs AJ, Shuhaiber J, Salemi A, Isom OW, Sedrakyan A. National trends in utilization and in-hospital outcomes of mechanical versus bioprosthetic aortic valve replacements. J Thorac Cardiovasc Surg. 2015;149:1262.e3-1269.e3. doi: 10.1016/j. jtcvs.2015.01.052.
3. Pokorney SD, Rao MP, Wojdyla DM, Gersh BJ, Lopes RD, Lewis BS, Hanna M, Avezum A, Wallentin L, Alexander JH, Granger CB. Apixaban use in patients with atrial fibrillation with bioprosthetic valves: insights from ARISTOTLE. Circulation 2015;132:A17277.
4. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104. doi: 10.1056/NEJMoa1310907.
5. Renda G, De Caterina R, Carnicelli A, Nordio F, Mercuri M, Ruff C, Giugliano R. Outcomes in 2824 patients with valvular heart disease treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 TRIAL. J Am Coll Cardiol. 2016; 67: 2194-2194.